Last reviewed · How we verify

Viral CTLs — Competitive Intelligence Brief

Viral CTLs (Viral CTLs) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune modulator. Area: Infectious disease.

phase 3 Immune modulator CD8+ T cells Infectious disease Biologic Live · refreshed every 30 min

Target snapshot

Viral CTLs (Viral CTLs) — New York Medical College. Viral CTLs stimulate the body's immune response to fight viral infections.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Viral CTLs TARGET Viral CTLs New York Medical College phase 3 Immune modulator CD8+ T cells
conventional medicine + TCM conventional medicine + TCM Henan University of Traditional Chinese Medicine phase 3 Immune modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune modulator class)

  1. Astellas Pharma China, Inc. · 1 drug in this class
  2. Henan University of Traditional Chinese Medicine · 1 drug in this class
  3. New York Medical College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Viral CTLs — Competitive Intelligence Brief. https://druglandscape.com/ci/viral-ctls. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: